Inhibrx Biosciences, Inc.
INBX Nasdaq
SEC CIK 2007919
Follow Inhibrx Biosciences
Weekly email: filings, results
Revenue, last quarter
$2M
Net income
−$38.7M
−9.9% vs same quarter last year
EPS, diluted
−$2.46
−7.9% vs same quarter last year
Operating cash flow
−$34.6M
−2.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.3M | −$140.1M |
| FY24 | $200K | $1.7B |
| FY23 | $1.8M | −$241.4M |
| FY22 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −10386.5% | −10773.5% |
| FY24 | −165724% | 843786% |
| FY23 | −12178.9% | −13408.9% |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$129.8M |
| FY24 | −$197M |
| FY23 | −$197.9M |
| FY22 | - |
- Inhibrx Biosciences
- Healthcare median
Show the numbers
| Year | Inhibrx Biosciences | Healthcare median |
|---|---|---|
| FY25 | −10773.5% | −30.6% |
| FY24 | 843786% | −47% |
| FY23 | −13408.9% | −58% |
| FY22 | - | −80.4% |